Physician profile
Robert Litman
NPI 1114041274
$59,893.92
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $8,461 · 2021: $148 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $48,320.77 | 2019-2020 | |
| Allergan, INC. | $8,647.82 | 2019-2020 | |
| F. Hoffmann-La Roche Ag | $2,590.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $133.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $120.18 | 2022 | |
| Abbvie INC. | $56.05 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $13.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $11.46 | 2020 |
15 companies reported research payments only; those appear in the research section below.
Research and ownership
$107.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Litman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.